新型抗癌药物肾毒性的最新进展

Update on the nephrotoxicity of novel anticancer agents .

作者信息

Nussbaum Eliezer Zachary, Perazella Mark A

出版信息

Clin Nephrol. 2018 Mar;89(3):149-165. doi: 10.5414/CN109371.

Abstract

Anticancer drug-induced kidney disease is a problem commonly encountered by nephrologists. The number of medications employed by oncologists causing acute and chronic kidney injury as well as electrolyte and acid-base disturbances has increased significantly over the past several decades. While conventional chemotherapeutic drugs induce a number of kidney lesions, emergence of very effective and well-tolerated targeted therapies and novel immunotherapies has increased the occurrence of drug-induced acute and chronic kidney injury in cancer patients. This article will review the various kidney lesions observed with these new classes of anticancer drugs. .

摘要

抗癌药物所致的肾脏疾病是肾病学家常遇到的问题。在过去几十年里，肿瘤学家使用的导致急性和慢性肾损伤以及电解质和酸碱平衡紊乱的药物数量显著增加。虽然传统化疗药物会引发多种肾脏病变，但高效且耐受性良好的靶向治疗药物和新型免疫治疗药物的出现，增加了癌症患者药物性急性和慢性肾损伤的发生率。本文将综述这些新型抗癌药物所导致的各种肾脏病变。